Amprenavir
From Wikipedia, the free encyclopedia
Amprenavir
|
|
Systematic (IUPAC) name | |
tetrahydrofuran-3-yl [3-[(4-aminophenyl)sulfonyl- (2-methylpropyl) amino] -1-benzyl-2- hydroxy-propyl] aminomethanoate | |
Identifiers | |
CAS number | |
ATC code | J05 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C25H35N3O6S |
Mol. mass | 505.628 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 90% |
Metabolism | ? |
Half life | 7.1-10.6 hours |
Excretion | ? |
Therapeutic considerations | |
Licence data |
|
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Amprenavir (Agenerase®) is a protease inhibitor used to treat HIV. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200mg, delivered in eight very large gel capsules. Production of amprenavir was discontinued by the manufacturer December 31, 2004.
Antivirals (primarily J05A, also S01AD and D06BB) | |
---|---|
Anti-herpesvirus | Aciclovir, Cidofovir, Docosanol, Famciclovir, Fomivirsen, Foscarnet, Ganciclovir, Idoxuridine, Penciclovir, Trifluridine, Tromantadine, Valaciclovir, Valganciclovir, Vidarabine |
Anti-influenza agents | Amantadine, Arbidol, Oseltamivir, Peramivir, Rimantadine, Zanamivir |
Antiretrovirals: NRTIs | Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Zalcitabine, Zidovudine |
Antiretrovirals: NtRTIs | Tenofovir |
Antiretrovirals: NNRTIs | Efavirenz, Delavirdine, Nevirapine, Loviride |
Antiretrovirals: PIs | Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir |
Antiretrovirals: Fusion inhibitors | Enfuvirtide |
Other antiviral agents | Adefovir, Fomivirsen, Imiquimod, Inosine, Interferon, Podophyllotoxin, Ribavirin, Viramidine |